https://www.selleckchem.com/products/osmi-4.html
0 months in the HAICAP group and 5.6 months in the HAIC group (p = 0.006; HR = 0.65; 95% CI 0.43-0.87). The disease control rate in overall response (83% vs 66%; p = 0.006) and intrahepatic response (85% vs 74%, respectively; p = 0.045) were higher in the HAICAP group than in the HAIC group. In comparison to HAIC, HAICAP was associated with a better treatment response and survival benefits for patients with advanced HCC. In comparison to HAIC, HAICAP was associated with a better treatment response and survival benefits for patients with